Literature DB >> 20547695

Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.

Seishi Ogawa1, Lee-Yung Shih, Takahiro Suzuki, Makoto Otsu, Hiromitsu Nakauchi, H Phillip Koeffler, Masashi Sanada.   

Abstract

c-CBL encodes a 120-kDa protein involved in intracellular signal transduction in a wide variety of cell types. Recently, frequent mutations of c-CBL have been reported in myeloid neoplasms showing both myelodysplastic and myeloproliferative features, in which most mutations are present in a homozygous state, as a result of allelic conversion in 11q. c-CBL has ubiquitin E3 ligase activity for a wide variety of tyrosine kinases, and thereby, negatively regulates tyrosine kinase signaling. Accordingly, c-CBL seems to have tumor suppressor functions, loss of which promotes tumorigenesis. On the other hand, once mutated, it is converted to an oncogenic protein and commits to myeloid leukemogenesis through a kind of gain of function causing aberrant signal transduction. The inhibition of mutant CBL protein or signaling pathways that it activates would have a role in therapeutics of myeloid neoplasms with CBL mutations. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547695     DOI: 10.1158/1078-0432.CCR-09-2341

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.

Authors:  Yuka Saito; Yoko Aoki; Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski; Masue Imaizumi; Takeshi Rikiishi; Yoji Sasahara; Shigeo Kure; Tetsuya Niihori; Shigeru Tsuchiya; Seiji Kojima; Yoichi Matsubara
Journal:  Leuk Res       Date:  2012-05-14       Impact factor: 3.156

2.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Authors:  Anand Pathak; Alexander Pemov; Mary L McMaster; Ramita Dewan; Sarangan Ravichandran; Evgenia Pak; Amalia Dutra; Hyo Jung Lee; Aurelie Vogt; Xijun Zhang; Meredith Yeager; Stacie Anderson; Martha Kirby; Neil Caporaso; Mark H Greene; Lynn R Goldin; Douglas R Stewart
Journal:  Hum Genet       Date:  2015-05-05       Impact factor: 4.132

4.  Hrs and STAM function synergistically to bind ubiquitin-modified cargoes in vitro.

Authors:  Hirohide Takahashi; Jonathan R Mayers; Lei Wang; J Michael Edwardson; Anjon Audhya
Journal:  Biophys J       Date:  2015-01-06       Impact factor: 4.033

5.  High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions.

Authors:  Eric A Kumar; Casey D Charvet; G L Lokesh; Amarnath Natarajan
Journal:  Anal Biochem       Date:  2010-12-01       Impact factor: 3.365

6.  Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain.

Authors:  Eric A Kumar; Ziyan Yuan; Nicholas Y Palermo; Lin Dong; Gulzar Ahmad; G L Lokesh; Carol Kolar; Smitha Kizhake; Gloria E O Borgstahl; Hamid Band; Amarnath Natarajan
Journal:  J Med Chem       Date:  2012-03-19       Impact factor: 7.446

7.  Indispensable roles of mammalian Cbl family proteins as negative regulators of protein tyrosine kinase signaling: Insights from in vivo models.

Authors:  Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Commun Integr Biol       Date:  2011-03

Review 8.  Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?

Authors:  J DeGregori
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

9.  CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.

Authors:  Junichi Watanabe; Ken Sato; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Reina Hikota-Saga; Takaaki Maekawa; Takeshi Yamamura; Ayako Kobayashi; Shinichi Kobayashi; Fumihiko Kimura
Journal:  Int J Hematol       Date:  2018-03-29       Impact factor: 2.490

10.  UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Authors:  S Goyama; J Schibler; A Gasilina; M Shrestha; S Lin; K A Link; J Chen; S P Whitman; C D Bloomfield; D Nicolet; S A Assi; A Ptasinska; O Heidenreich; C Bonifer; T Kitamura; N N Nassar; J C Mulloy
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.